AR128391A1 - POL THETA INHIBITORS - Google Patents
POL THETA INHIBITORSInfo
- Publication number
- AR128391A1 AR128391A1 ARP230100220A ARP230100220A AR128391A1 AR 128391 A1 AR128391 A1 AR 128391A1 AR P230100220 A ARP230100220 A AR P230100220A AR P230100220 A ARP230100220 A AR P230100220A AR 128391 A1 AR128391 A1 AR 128391A1
- Authority
- AR
- Argentina
- Prior art keywords
- pol theta
- theta inhibitors
- polq
- dna polymerase
- enzyme dna
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 102100029766 DNA polymerase theta Human genes 0.000 abstract 4
- 108010093204 DNA polymerase theta Proteins 0.000 abstract 2
- 101001094659 Homo sapiens DNA polymerase kappa Proteins 0.000 abstract 2
- 101000865085 Homo sapiens DNA polymerase theta Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se relaciona con compuestos de fórmula (1), que poseen actividad inhibidora de la enzima ADN polimerasa theta (POLQ), métodos para su preparación, composiciones farmacéuticas que los contienen y su uso en el tratamiento o prevención de enfermedades o afecciones que involucran a la enzima ADN polimerasa theta (POLQ).The present invention relates to compounds of formula (1), which have inhibitory activity of the enzyme DNA polymerase theta (POLQ), methods for their preparation, pharmaceutical compositions containing them and their use in the treatment or prevention of diseases or conditions that They involve the enzyme DNA polymerase theta (POLQ).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202241005153 | 2022-01-31 | ||
IN202241006844 | 2022-02-09 | ||
IN202241007579 | 2022-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR128391A1 true AR128391A1 (en) | 2024-04-24 |
Family
ID=85198983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP230100220A AR128391A1 (en) | 2022-01-31 | 2023-01-30 | POL THETA INHIBITORS |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR128391A1 (en) |
TW (1) | TW202332442A (en) |
WO (1) | WO2023144793A1 (en) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4080330A (en) * | 1975-06-23 | 1978-03-21 | Delmar Chemicals Limited | Phenylindolines and process for their production |
US4584292A (en) * | 1984-10-19 | 1986-04-22 | Kotobuki Seiyaku Co., Ltd. | Antihypertensive 1,5-benzothiazepine derivatives and compositions thereof |
CN105330644B (en) * | 2015-11-18 | 2017-12-19 | 中国农业大学 | (The base of 1,2,3,4 tetrahydroquinoline 1)(Substituted pyrazolecarboxylic base)First ketone compounds and its application |
US20220098154A1 (en) | 2019-01-30 | 2022-03-31 | Ideaya Biosciences, Inc. | Acetamido derivatives as dna polymerase theta inhibitors |
CA3127642A1 (en) | 2019-01-31 | 2020-08-06 | Ideaya Biosciences, Inc. | Heteroarylmethylene derivatives as dna polymerase theta inhibitors |
US20230078112A1 (en) | 2019-05-31 | 2023-03-16 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives |
WO2021028643A1 (en) | 2019-08-09 | 2021-02-18 | Artios Pharma Limited | Heterocyclic compounds for use in the treatment of cancer |
CN114728036A (en) | 2019-08-09 | 2022-07-08 | 阿提奥斯医药有限公司 | Novel therapeutic uses |
GB201918587D0 (en) | 2019-12-17 | 2020-01-29 | Artios Pharma Ltd | Novel compounds |
WO2022026548A1 (en) * | 2020-07-29 | 2022-02-03 | Ideaya Biosciences, Inc. | Acetamido-amino and acetamido-sulfur derivatives as dna polymerase theta inhibitors |
EP4188918A1 (en) * | 2020-07-29 | 2023-06-07 | Ideaya Biosciences, Inc. | Cyclized acetamido derivatives as dna polymerase theta inhibitors |
-
2023
- 2023-01-30 AR ARP230100220A patent/AR128391A1/en unknown
- 2023-01-30 WO PCT/IB2023/050798 patent/WO2023144793A1/en unknown
- 2023-01-30 TW TW112103145A patent/TW202332442A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202332442A (en) | 2023-08-16 |
WO2023144793A1 (en) | 2023-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022020841A2 (en) | CAST TRICYCLIC KRAS INHIBITORS | |
ECSP21080740A (en) | NLRP3 INFLAMASOME INHIBITORS | |
CL2021000191A1 (en) | Nlrp3 inflammasome inhibitors | |
EA202091491A1 (en) | NEW BENZYLAMINE SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | |
BR112015022462A8 (en) | acid inhibitors, pharmaceutical composition, method of inhibiting indolamine 2,3-dioxigenase activity and use of said inhibitors | |
BR112022001324A2 (en) | Compound, pharmaceutical composition and method for treating a p38 map kinase-mediated disease in a subject in need thereof | |
BR112016028642A2 (en) | compound, pharmaceutical composition, method of treating a disease or condition, method of inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide, method of inhibiting immune reactions or overgrowth or destructive cancer cell proliferation, kit, and, use of a compound, salt, isomer or a pharmaceutically acceptable mixture thereof. | |
BR112022000503A2 (en) | Compounds Useful for Treating Influenza Virus Infections | |
BR112016028819A2 (en) | pharmaceutical composition, methods for treating a disease or condition in a human and for inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide and excessive or destructive immune reactions or cancer cell growth or proliferation, kit, compound, pharmaceutically acceptable salt , isomer or mixture thereof, and use of a compound, pharmaceutically acceptable salt or mixture thereof. | |
BR112021022061A2 (en) | kcnt1 inhibitors and methods of use | |
BR112023020781A2 (en) | CBL-B MODULATORS AND USES THEREOF | |
EA201590066A1 (en) | DIFTORGEXAHYDROCYCLOPENTAXOXASYNYLES AND DIFTORGEXAHYDROBENZOXASYNYLES AS BETA SECRETASE INHIBITORS | |
BR112023015210A2 (en) | CDK2 INHIBITORS AND METHODS OF USE THEREOF | |
BR112022020147A2 (en) | COMPOUNDS TO TREAT HUNTINGTON'S DISEASE | |
BR112017028616A2 (en) | zeste homolog 2 inhibitor enhancer | |
BR112022018067A2 (en) | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | |
EA202191955A1 (en) | MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS | |
MX2023012844A (en) | Class of xanthine oxidase inhibitors. | |
BR112023015425A2 (en) | URACILA DERIVATIVES AS TRPA1 INHIBITORS | |
MA39926B1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
BR112022013488A2 (en) | SUBSTITUTED PYRAZOLO-PYRIMIDINES AND THEIR USE | |
AR128391A1 (en) | POL THETA INHIBITORS | |
BR112022012737A2 (en) | PD-L1 ANTAGONIST COMPOUND | |
CL2017002229A1 (en) | Bace1 inhibitors. | |
EA202190766A1 (en) | IMMUNOMODULATORS, THEIR COMPOSITIONS AND METHODS OF APPLICATION |